Highlights

• Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with ⁶⁷Cu SAR-bisPSMA at the lowest dose level of 4GBq.
• No dose limiting toxicities (DLTs) have been reported in cohort 1.
• The Safety Review Committee (SRC) has recommended that the trial...